1. Sönmezer MÇ, Tülek N. Bakteriyel infeksiyonlarda ve sepsiste biyobelirteçler. Klimik Derg 2015; 28: 96-102.
2. Puntmann VO. How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease. Postgrad Med J 2009; 85:538–545.
3. Marshall JC, Reinhart K, International Sepsis F. Biomarkers of sepsis. Crit Care Med 2009; 37:2290–2298.
4. Kaplan JM, Wong HR. Biomarker discovery and development in pediatric critical care medicine. Pediatr Crit Care Med 2011; 12:165–173.
5. Jacobs L, Wong HR. Emerging infection and sepsis biomarkers: will they change current therapies? Expert Rev Anti Infect Ther 2016; 14:929-941.
6. Biomarkers of Infection and Inflammation. https://clsjournal.ascls.org/content/ascls/early/2020/01/20/ascls.119.001891.full.pdf
7. Kushner I, Antonelli M. Acute phase reactants.UpToDate
8. Plebani M. Why C-reactive protein is one of the most requested tests in clinical laboratories? Clin Chem Lab Med 2023; 61:1540-1545.
9. Coster D, Wasserman A, Fisher E, et al. Using the kinetics of C-reactive protein response to improve the differential diagnosis between acute bacterial and viral infections. Infection.
2020;48:241-248.
10. Tan M, Lu Y, Jiang H, Zhang L. The diagnostic accuracy of procalcitonin and C-reactive protein for sepsis: A systematic review and meta-analysis. J Cell Biochem 2019; 120:5852-5859.
11. Parlato M, Philippart F, Rouquette A, et al. Circulating biomarkers may be unable to detect infection at the early phase of sepsis in ICU patients: the CAPTAIN prospective multicenter cohort
study. Intensive Care Med 2018; 44:1061–1070.
12. Povoa P, Coelho L, Dal-Pizzol F, et al. How to use biomarkers of infection or sepsis at the bedside: guide to clinicians. Intensive Care Med 2023; 49:142-153.
13. Levinson T, Tamir N, Shenhar-Tsarfaty S, et al. The potential benefit of a second C-reactive protein measurement in patients with gram-negative bacteraemia presenting to the emergency
medicine department. Biomarkers 2020; 25:533-538.
14. Smedemark SA, Aabenhus R, Llor C, Fournaise A, Olsen O, Jorgensen KJ. Biomarkers as point-of-care tests to guide prescription of antibiotics in people with acute respiratory infections in
primary care. Cochrane Database Syst Rev 2022; 10:CD010130.
15. Schmit X, Vincent JL. The time course of blood C-reactive protein concentrations in relation to the response to initial antimicrobial therapy in patients with sepsis. Infection 2008; 36:213-219.
16. Lisboa T, Seligman R, Diaz E, Rodriguez A, Teixeira PJ, Rello J. C-reactive protein correlates with bacterial load and appropriate antibiotic therapy in suspected ventilator-associated pneumo-
nia. Crit Care Med 2008; 36:166–171.
17. Whicher J, Bienvenu J, Monneret G. Procalcitonin as an acute phase marker. Ann Clin Biochem 2001; 38:483-493.
18. Mohan A, Harikrishna J. Biomarkers for the diagnosis of bacterial infections: in pursuit of the ‘Holy Grail’. Indian J Med Res 2015; 141:271-273.
19. Lin JLJ. 2021. Procalcitonin (PCT). https://emedicine.medscape.com/article/2096589-overview
20. Schuetz P, Beishuizen A, Broyles M, et al. Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use. Clin Chem Lab Med 2019; 57:1308-
1318.
21. Bassetti M, Russo A, Righi E, et al. Role of procalcitonin in predicting etiology in bacteremic patients: Report from a large single-center experience. J Infect Public Health 2020; 13:40-45.
22. Wacker C, Prkno A, Brunkhorst FM, et al. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 2013; 13:426–435.
23. Hattori T, Nishiyama H, Kato H, et al. Clinical value of procalcitonin for patients with suspected bloodstream infection. Am J Clin Pathol 2014; 141:43–51.
24. Laukemann S, Kasper N, Kulkarni P, et al. Can we reduce negative blood cultures with clinical scores and blood markers? results from an observational cohort study. Medicine (Baltimore)
2015; 94:e2264.
25. Goodlet KJ, Cameron EA, Nailor MD. Low Sensitivity of Procalcitonin for Bacteremia at an Academic Medical Center: A Cautionary Tale for Antimicrobial Stewardship. Open Forum Infect
Dis 2020; 7:ofaa096.
26. Garcia-Granero A, Frasson M, Flor-Lorente B, et al. Procalcitonin and C-reactive protein as early predictors of anastomotic leak in colorectal surgery. Dis Colon Rectum20 13; 56:475-483.
27. Zielinska-Borkowska U, Dib N, Tarnowski W, et al. Monitoring of procalcitonin but not interleukin-6 is useful for the early prediction of anastomotic leakage after colorectal surgery. Clin
Chem Lab Med 2017; 55:1053–9.
28. Giaccaglia V, Salvi PF, Antonelli MS, et al. Procalcitonin reveals early dehiscence in colorectal surgery: the PREDICS Study. Ann Surg 2016; 263:967-972.
29. Jebali MA, Hausfater P, Abbes Z, Aouni Z, Riou B, Ferjani M. Assessment of the accuracy of procalcitonin to diagnose postoperative infection after cardiac surgery. Anesthesiology 2007;
107:232-238.
30. Klingele M, Bomberg H, Poppleton A, et al. Elevated procalcitonin in patients after cardiac surgery: a hint to nonocclusive mesenteric ischemia. Ann Thorac Surg 2015; 99:1306-1312.
31? Rodriguez AH, Aviles-Jurado FX, Diaz E, et al. Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: a CHAID decision-tree analysis. J Infect 2016;
72:143–151
32. Self WH, Balk RA, Grijalva CG, et al. Procalcitonin as a Marker of Etiology in Adults Hospitalized With Community-Acquired Pneumonia. Clin Infect Dis 2017; 65:183-190.
33. Sungurlu S, Balk RA. The Role of Biomarkers in the Diagnosis and Management of Pneumonia. Infect Dis Clin North Am 2024; 38:35-49.
34. Heilmann E, Gregoriano C, Schuetz P. Biomarkers of Infection: Are They Useful in the ICU? Semin Respir Crit Care Med 2019; 40:465-475.
35. Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2017; 10:CD007498
36. Kyriazopoulou E, Liaskou-Antoniou L, Adamis G, et al. Procalcitonin to Reduce Long-Term Infection-associated Adverse Events in Sepsis. A Randomized Trial. Am J Respir Crit Care Med
2021; 203:202-210.
37. Schuetz P, Maurer P, Punjabi V, Desai A, Amin DN, Gluck E. Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients. Crit Care 2013; 17:R115.
38. Mantovani A, Garlanda C. Humoral Innate Immunity and Acute-Phase Proteins. N Engl J Med 2023; 388:439-452.
39. de Kruif MD, Limper M, Sierhuis K, et al. PTX3 predicts severe disease in febrile patients at the emergency department. J Infect 2010; 60: 122–127.
40. Uusitalo-Seppälä R, Huttunen R, Aittoniemi J, et al. Pentraxin 3 (PTX3) is associated with severe sepsis and fatal disease in emergency room patients with suspected infection: a prospective
cohort study. PLoS One 2013; 8:e53661.
41. Mauri T, Bellani G, Patroniti N, et al. Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. Intensive Care Med
2010; 36: 621–629.
42. Huttunen R, Hurme M, Aittoniemi J, et al. High plasma level of long pentraxin 3 (PTX3) is associated with fatal disease in bacteremic patients: a prospective cohort study. PLoS One 2011; 6:
e17653.
43. Chenevier-Gobeaux C, Borderie D, Weiss N, Mallet-Coste T, Claessens YE. Presepsin (sCD14-ST), an innate immune response marker in sepsis. Clin Chim Acta 2015; 450:97-103.
44. Masson, S., Caironi, P., Fanizza, C. et al. Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter,
randomized ALBIOS trial. Intensive Care Med 2015; 41:12–20.
45. Memar MY, Baghi HB. Presepsin: A promising biomarker for the detection of bacterial infections. Biomed Pharmacother 2019; 111:649-656.
46. Paraskevas T, Chourpiliadi C, Demiri S, et al. Presepsin in the diagnosis of sepsis. Clin Chim Acta 2023; 550:117588
47. Kondo Y, Umemura Y, Hayashida K, Hara Y, Aihara M, Yamakawa K. Diagnostic value of procalcitonin and presepsin for sepsis in critically ill adult patients: a systematic review and meta-a-
nalysis. J Intensive Care 2019; 7:22.
48. Mierzchała-Pasierb M, Lipińska-Gediga M. Sepsis diagnosis and monitoring – procalcitonin as standard, but what next?. Anaesthesiology Intensive Therapy 2019; 51:299-305.
49. Aliu-Bejta A, Kurshumliu M, Namani S, Dreshaj S, Barsić B. Ability of presepsin concentrations to predict mortality in adult patients with sepsis. J Clin Transl Sci. 2023 May 3;7(1):e121.
50. de Nooijer AH, Pickkers P, Netea MG, Kox M. Inflammatory biomarkers to predict the prognosis of acute bacterial and viral infections. J Crit Care 2023; 78:154360.
51. Lundberg OHM, Rosenqvist M, Bronton K, Schulte J, Friberg H, Melander O. Bioactive adrenomedullin in sepsis patients in the emergency department is associated with mortality, organ
failure and admission to intensive care. PLoS One 2022; 17:e0267497.
52. Liang J, Cai Y, Shao Y. Comparison of presepsin and Mid-regional pro-adrenomedullin in the diagnosis of sepsis or septic shock: a systematic review and meta-analysis. BMC Infect Dis 2023;
23:288.
53. Andaluz-Ojeda D, Nguyen HB, Meunier-Beillard N, et al. Superior accuracy of mid-regional proadrenomedullin for mortality prediction in sepsis with varying levels of illness severity. Ann
Intensive Care 2017;7:15.
54. Koehler P, Cornely OA, Böttiger BW, et al. COVID-19 associated pulmonary aspergillosis. Mycoses 2020; 63:528-534.,
55. Donnelly JP, Chen SC, Kauffman CA, et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of
Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis 2020; 71:1367-1376.
56. Fang W, Wu J, Cheng M, et al. Diagnosis of invasive fungal infections: challenges and recent developments. J Biomed Sci 2023; 30:42.
57. Sulahian A, Porcher R, Bergeron A, et al. Use and limits of (1-3)-β-d-glucan assay (Fungitell), compared to galactomannan determination (Platelia Aspergillus), for diagnosis of invasive
aspergillosis. J Clin Microbiol 2014; 52:2328-2833.
58. Leeflang MM, Debets-Ossenkopp YJ, Wang J, et al. Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev. 2015; 2015:CD007394.
59. Patterson TF. Diagnosis of invasive aspergillosis. UpToDate.
60. Bukkems LMP, van Dommelen L, Regis M, van den Heuvel E, Nieuwenhuizen L. The Use of Galactomannan Antigen Assays for the Diagnosis of Invasive Pulmonary Aspergillosis in the
Hematological Patient: A Systematic Review and Meta-Analysis. J Fungi (Basel) 2023; 9:674.
61. Azim A, Ahmed A. Diagnosis and management of invasive fungal diseases in non-neutropenic ICU patients, with focus on candidiasis and aspergillosis: a comprehensive review. Front Cell
Infect Microbiol 2024; 14:1256158.